Immune System Diseases clinical trials

Explore recruiting immune system diseases clinical trials.

Recruiting immune system diseases studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Immune System Diseases trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

Long-term extension study to evaluate the safety and efficacy of riliprubart (SAR445088) in participants with chronic inflammatory demyelinating polyneuropathy (CIDP)

Portugal, Poland, Belgium, Hungary, Czechia, Greece +8 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

An open-label Phase 2 study to investigate the efficacy and safety of rilzabrutinib in adult participants with Graves’ disease

Spain, Italy, Germany, Greece, Hungary

Therapeutic exploratory (Phase II) EU CTIS Study details

A study to investigate how different tablet types of balinatunfib and food will influence the absorption of balinatunfib in blood in healthy adult participants

Belgium

Human Pharmacology (Phase I)- Other EU CTIS Study details

A parallel-group treatment, Phase 2a, multicenter, randomized, double-blind, placebo-controlled umbrella study to evaluate the efficacy and safety of frexalimab, brivekimig and rilzabrutinib in participants aged 16 to 75 years with primary focal segmental glomerulosclerosis (FSGS) or minimal change disease (MCD)

Hungary, Portugal, Italy, France, Germany, Spain +5 more

Therapeutic exploratory (Phase II) EU CTIS Study details

Effect of SAR445611 on inflammatory responses following LPS challenge study in healthy participants

Netherlands

Human Pharmacology (Phase I)- Other EU CTIS Study details

First-in-human study of SAR445611 in healthy adult participants

Belgium

Human Pharmacology (Phase I)- First administration to humans EU CTIS Study details

Immune System Diseases trials by city

Immune System Diseases in Toronto Immune System Diseases in Vancouver Immune System Diseases in Montreal Immune System Diseases in Calgary Immune System Diseases in Edmonton Immune System Diseases in Ottawa Immune System Diseases in Winnipeg Immune System Diseases in Quebec City Immune System Diseases in Hamilton Immune System Diseases in Kitchener Immune System Diseases in London Immune System Diseases in Halifax Immune System Diseases in New York Immune System Diseases in Los Angeles Immune System Diseases in Chicago Immune System Diseases in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease